当前位置: X-MOL 学术Physiol. Behav. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effects of pramlintide on energy intake and food preference in rats given a choice diet
Physiology & Behavior ( IF 2.9 ) Pub Date : 2021-07-30 , DOI: 10.1016/j.physbeh.2021.113541
Katherine A Kern 1 , Adrianne M DiBrog 1 , Johnathan T Przybysz 1 , Elizabeth G Mietlicki-Baase 2
Affiliation  

Amylin is a peptide hormone involved in the control of energy balance, making the amylin system a potential target for pharmacotherapies to treat obesity. Pramlintide, an amylin analogue, is an FDA-approved medication for the treatment of diabetes that also has food intake- and body weight-suppressive effects. However, it is unknown whether pramlintide may preferentially reduce intake of highly palatable, energy dense food, the overconsumption of which is thought to play a role in the etiology of obesity. Here, we investigate the effects of pramlintide on food intake and body weight in rats given a choice of chow and high fat diet (HFD). Systemic pramlintide injection in rats reduced HFD intake at 3h post-injection, with no effects at other times and no significant effects on chow intake, body weight, or percent preference for HFD. In a separate experiment, the effects of central injection of pramlintide on food intake and body weight were similarly evaluated. Intracerebroventricular pramlintide significantly reduced HFD intake throughout the 24h post-injection, with some suppressive effects on chow intake, and also decreased 24h body weight change. Again, no significant changes were observed in the proportion of calories obtained from HFD. The same intracerebroventricular doses of pramlintide did not induce pica, suggesting that pramlintide-mediated reductions in feeding are not due to nausea/malaise. Our results suggest that pramlintide reduces food intake in rats largely via reductions in intake of HFD versus chow, supporting the idea that the potent effects of pramlintide on palatable food intake may have utility in the treatment of obesity.



中文翻译:

普兰林肽对选择饮食大鼠能量摄入和食物偏好的影响

胰淀素是一种参与控制能量平衡的肽激素,使胰淀素系统成为药物疗法治疗肥胖症的潜在靶点。普兰林肽是一种胰淀素类似物,是 FDA 批准的用于治疗糖尿病的药物,它还具有抑制食物摄入和体重的作用。然而,尚不清楚普兰林肽是否会优先减少高度可口、能量密集的食物的摄入,过度食用被认为在肥胖的病因中起作用。在这里,我们研究了在选择食物和高脂肪饮食 (HFD) 的情况下,普兰林肽对大鼠食物摄入和体重的影响。大鼠全身注射普兰林肽在注射后 3 小时减少了 HFD 摄入量,在其他时间没有影响,对食物摄入量、体重或对 HFD 的偏好百分比没有显着影响。在另一项实验中,同样评估了中枢注射普兰林肽对食物摄入和体重的影响。脑室内普兰林肽在整个注射后 24 小时内显着降低了 HFD 摄入量,对食物摄入量有一些抑制作用,并且还降低了 24 小时体重变化。同样,从 HFD 获得的卡路里比例没有明显变化。相同脑室内剂量的普兰林肽不会引起异食癖,这表明普兰林肽介导的进食减少不是由于恶心/不适。我们的研究结果表明,与食物相比,普兰林肽主要通过减少 HFD 摄入量来减少大鼠的食物摄入,这支持了普兰林肽对可口食物摄入的有效影响可能对治疗肥胖症有用的观点。类似地评估了普兰林肽中枢注射对食物摄入和体重的影响。脑室内普兰林肽在整个注射后 24 小时内显着降低了 HFD 摄入量,对食物摄入量有一些抑制作用,并且还降低了 24 小时体重变化。同样,从 HFD 获得的卡路里比例没有明显变化。相同脑室内剂量的普兰林肽不会引起异食癖,这表明普兰林肽介导的进食减少不是由于恶心/不适。我们的研究结果表明,与食物相比,普兰林肽主要通过减少 HFD 摄入量来减少大鼠的食物摄入,这支持了普兰林肽对可口食物摄入的有效影响可能对治疗肥胖症有用的观点。类似地评估了普兰林肽中枢注射对食物摄入和体重的影响。脑室内普兰林肽在整个注射后 24 小时内显着降低了 HFD 摄入量,对食物摄入量有一些抑制作用,并且还降低了 24 小时体重变化。同样,从 HFD 获得的卡路里比例没有明显变化。相同脑室内剂量的普兰林肽不会引起异食癖,这表明普兰林肽介导的进食减少不是由于恶心/不适。我们的研究结果表明,与食物相比,普兰林肽主要通过减少 HFD 摄入量来减少大鼠的食物摄入,这支持了普兰林肽对可口食物摄入的有效影响可能对治疗肥胖症有用的观点。

更新日期:2021-08-04
down
wechat
bug